Background: Polo like kinase 1 (PLK1) is frequently upregulated in tumors and is thus viewed as a promising therapeutic target in various cancers. Several PLK1 inhibitors have recently been developed and clinically tested in solid cancers, albeit with limited success. So far, no predictive biomarkers for PLK1 inhibitors have been established. To this end, we conducted a post-hoc biomarker analysis of tumor samples from non-small cell lung cancer (NSCLC) patients treated with the PLK1 inhibitor BI2536 in a phase II study. Methods: We analyzed formalin-fixed paraffin-embedded surplus tumor tissue from 47 study patients using immunohistochemistry (IHC) and DNA sequencing of KRAS, EGFR, BRAF, and PIK3CA. Results:KRAS-mutated patients showed numerically prolonged progression-free survival, but statistical significance was not established. Interestingly, when pathways rather than single genes were analyzed, a positive correlation between IHC staining of activated ERK (p-ERK) and mutated KRAS was detected, whereas KRAS mutation status was found to be negatively correlated with activated AKT (p-AKT). Conclusion: With this hypothesis-generating study in BI2531-treated patients, we could not establish a correlation between KRAS mutations and relevant clinical endpoints. Future clinical trials with concomitant systematic biosampling and comprehensive molecular analyses are required to identify biomarkers predictive for response to PLK1 inhibitors.

Journal Section:
Original Article
Keywords:
NSCLC, BI2536, KRAS, Lung cancer, PLK1
1.
Forbes SA, Bindal N, Bamford S, et al.: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-D950.
2.
Ahrendt SA, Decker PA, Alawi EA, et al.: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-1530.
3.
Riely GJ, Kris MG, Rosenbaum D, et al.: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
4.
Skoulidis F, Byers LA, Diao L, et al.: Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 2015;5:860-877.
5.
Zer A, Ding K, Lee SM, et al.: Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol 2016;11:312-323.
6.
Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2014;503:548-551.
7.
Patricelli MP, Janes MR, Li LS, et al.: Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov 2016;6:316-329.
8.
Zimmermann G, Papke B, Ismail S, et al.: Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013;497:638-642.
9.
Scholl C, Fröhling S, Dunn IF, et al.: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137:821-834.
10.
Luo J, Emanuele MJ, Li D, et al.: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-848.
11.
Barr FA, Silljé HHW, Nigg EA: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5:429-440.
12.
Eckerdt F, Yuan J, Strebhardt K: Polo-like kinases and oncogenesis. Oncogene 2005;24:267-276.
13.
Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-330.
14.
Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287-291.
15.
Yim H: Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 2013;24:999-1006.
16.
Berg A, Berg T: Inhibitors of the polo-box domain of polo-like kinase 1. Chembiochem 2016;17:650-656.
17.
Mross K, Dittrich C, Aulitzky WE, et al.: A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012;107:280-286.
18.
Mross K, Frost A, Steinbild S, et al.: Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:5511-5517.
19.
Schöffski P, Awada A, Dumez H, et al.: A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012;48:179-186.
20.
Schöffski P, Blay J-Y, De Greve J, et al.: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010;46:2206-2215.
21.
Sebastian M, Reck M, Waller CF, et al.: The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010;5:1060-1067.
22.
Reis H, Herold T, Ting S, et al.: HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. Lung Cancer 2015;88:34-41.
23.
Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGN): A genomics-based classification of human lung tumors. Sci Transl Med 2013;5:209ra153.
24.
Kris MG, Johnson BE, Berry LD, et al.: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006.
25.
Wiesweg M, Ting S, Reis H, et al.: Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. Eur J Cancer 2013;49:3076-3082.
26.
Barlesi F, Mazieres J, Merlio J-P, et al.: Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387:1415-1426.
27.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
28.
Archambault V, Lepine G, Kachaner D: Understanding the polo kinase machine. Oncogene 2015;34:4799-4807.
29.
Lu LY, Wood JL, Minter-Dykhouse K, et al.: Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol 2008;28:6870-6876.
30.
Yamamoto Y, Matsuyama H, Kawauchi S, et al.: Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006;70:231-237.
31.
Lu L-Y, Yu X: The balance of Polo-like kinase 1 in tumorigenesis. Cell Div 2009;4:4.
32.
Weichert W, Kristiansen G, Schmidt M, et al.: Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005;11:5644-5650.
33.
Steegmaier M, Hoffmann M, Baum A, et al.: BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-322.
34.
Hofheinz R-D, Al-Batran S-E, Hochhaus A, et al.: An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010;16:4666-4674.
35.
Liu XS, Song B, Elzey BD, et al.: Polo-like kinase 1 facilitates loss of PTEN tumor suppressor-induced prostate cancer formation. J Biol Chem 2011;286:1-19.
36.
Gjertsen BT, Schöffski P: Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2015;29:11-19.
37.
Borghaei H, Paz-Ares L, Horn L, et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-1639.
38.
Rittmeyer A, Barlesi F, Waterkamp D, et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-265.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.